Rein Therapeutics Inc.
RNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $13 | $17 | $5 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$13 | -$17 | -$5 | -$3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$28 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$63 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.51 | -3.42 | -6.02 | -5.89 |
| % Growth | -2.6% | 43.2% | -2.2% | – |
| Operating Cash Flow | -$22 | -$20 | -$25 | -$24 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$22 | -$20 | -$25 | -$24 |